Anticancer drug dosing in kidney dysfunction

The **International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD)** is a project led by eviQ and the Cancer Institute NSW.

The guideline is:

- a decision support tool for the management of anticancer drug dosing in kidney dysfunction
- a practical and standardised approach for all cancer practitioners
- based on current evidence and clinical consensus
- provides guidance on 59 anticancer drugs
- developed by an international, multidisciplinary working party.

External consultation of the draft guideline is planned for early 2022.

The guideline will be adapted into eviQ treatment protocols from mid 2022 onwards. Extensive communication to eviQ users will occur in advance of any changes.

Do you know the best method of assessing kidney function in your cancer patients?

- Directly measured glomerular filtration rate is the gold standard in determining kidney function and informing drug dosing decisions.
- For practicality, **estimated glomerular filtration rate calculated via the Chronic Kidney Disease – Epidemiology Collaboration (CKD-EPI) equation** (eGFR\textsubscript{CKD-EPI}) is a suitable alternative in most clinical scenarios. It is reported automatically in laboratory blood test reports and is more precise than other estimated methods for kidney function.

Test your knowledge with an interactive mini-quiz:

- Scan the QR code or go to [https://link.edapp.com/3txVbFYAGkb](https://link.edapp.com/3txVbFYAGkb) on your mobile device to install EdApp
- Follow the instructions to create an account
- Scroll to the quiz – Anticancer drug dosing in kidney dysfunction and complete it.

Consensus recommendations from the guideline

1. **Use eGFR\textsubscript{CKD-EPI}** to guide the assessment of kidney function, except when directly measured GFR is clinically necessary.

2. **Where the anticancer drug dose is dependent on kidney function, eGFR\textsubscript{CKD-EPI} is suggested to guide the dosing, except in specific circumstances involving platinum drugs and high-dose methotrexate.**

3. **The internationally accepted KDIGO chronic kidney disease categories are suggested to guide stepwise dose adjustments of anticancer drugs in kidney dysfunction.**

Find out more...

Have a look at eviQ's dedicated guideline webpage for videos from our working party experts and for further details about the guideline in eviQ. [eviq.org.au/pages/international-consensus-guideline-for-anticancer-d](http://eviq.org.au/pages/international-consensus-guideline-for-anticancer-d)